Study wrapper · #893
Beyond weight loss: multisystem benefits of obesity medications.
Savas M, Kuckuck S, Boon MR, et al. The lancet. Diabetes & endocrinology. 2026.
DOI: 10.1016/s2213-8587(26)00100-2PubMed: 42208956
Editor's note
This narrative review of obesity medications covers semaglutide and tirzepatide among many agents, summarizing multisystem benefits reported across RCTs and meta-analyses. Both peptides are genuine subjects but sit within a broad drug-class overview rather than a focused analysis. Useful context, though weight-loss-independent effects are described as accumulating rather than settled.
Plain-language abstract
This review synthesizes trial evidence that obesity medications, including semaglutide and tirzepatide, are associated with benefits across cardiovascular, metabolic, liver, kidney, and other conditions beyond weight loss.
Related coverage
Weak / none
A qualitative study exploring experiences about using semaglutide for weight loss in a rural setting in Denmark - 'she is probably on the meds'.
Scandinavian journal of primary health caren=——2026
Mixed
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers.
Annals of medicinen=——2026
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026